Karyopharm (NASDAQ: KPTI) EVP Mano receives 32,415 RSU award

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. executive Michael Mano, EVP, CLO & Secretary, received an equity award of 32,415 shares of common stock on January 31, 2026. The award was granted at a price of $0 per share under the company’s 2022 Equity Incentive Plan as restricted stock units.

The RSUs convert into common stock on a one-for-one basis and vest over time, with 50% of the shares vesting on January 31, 2027 and the remaining 50% vesting on January 31, 2028. Following this grant, Mano directly beneficially owns 97,490 shares of Karyopharm common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mano Michael

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CLO&Secretary

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		A		32,415(1)	A	$0	97,490	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.

	/s/ Nancy Smith as Attorney-in-Fact for Michael Mano	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Karyopharm executive Michael Mano report on this Form 4 for KPTI?

Michael Mano reported receiving 32,415 shares of Karyopharm common stock as a restricted stock unit award. The grant was made at $0 per share under the 2022 Equity Incentive Plan, increasing his directly owned holdings to 97,490 shares after the transaction.

How many KPTI shares did Michael Mano acquire in this transaction?

He acquired 32,415 shares of Karyopharm Therapeutics common stock through an RSU award. These shares were granted at no cash cost to him and are scheduled to vest in two equal installments in 2027 and 2028, subject to the plan’s terms.

When do Michael Mano’s newly granted KPTI RSUs vest?

The RSUs vest in two stages: 50% of the 32,415 shares vest on January 31, 2027, and the remaining 50% vest on January 31, 2028. Each vested RSU converts into one share of Karyopharm common stock upon settlement.

What is Michael Mano’s total KPTI share ownership after this Form 4 transaction?

After the reported award, Michael Mano directly beneficially owns 97,490 shares of Karyopharm Therapeutics common stock. This figure reflects his holdings immediately following the grant of 32,415 restricted stock units reported in the filing, all held in direct ownership form.

What role does Michael Mano hold at Karyopharm Therapeutics (KPTI)?

Michael Mano is an officer of Karyopharm Therapeutics, serving as Executive Vice President, Chief Legal Officer and Secretary. His Form 4 filing reflects equity compensation aligned with this senior leadership role, granted under the company’s 2022 Equity Incentive Plan.

Was there any cash paid for the KPTI shares reported in this Form 4?

No cash was paid for these shares. The 32,415 shares reported were granted at a price of $0 per share as restricted stock units under Karyopharm’s equity incentive plan, representing stock-based compensation rather than an open-market purchase.